Company / Cash & Equivalents
Aurinia Pharmaceuticals Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$80.2M
FY2025
5-year range
$48.8M / $272.4M
FY2021-FY2025
Trend
-3.9%
vs FY2024
Sector context
#159 of 207
Health Care
What the data says
Aurinia Pharmaceuticals Inc.'s cash & equivalents of $80M is lower than 77% of companies in the Health Care sector (FY2025). Improved from $49M to $80M over the past 2 years.
Based on SEC 10-K filings.
$80M in FY2025 with a 5-year CAGR of -21.7%.
Improved from $49M to $80M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -29.8%
- 5-Year CAGR
- -21.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 207This company $80.2M Sector average $669.5M
▼
-88.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -21.7%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 3.9% year-over-year.
- Ranks #159 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $80.2M | -3.9% |
| FY2024 | $83.4M | +71.1% |
| FY2023 | $48.8M | -79.0% |
| FY2022 | $231.6M | -14.9% |
| FY2021 | $272.4M | +0.0% |
| FY2020 | $272.4M | -11.0% |
| FY2019 | $306.0M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026